Maria Orr

TL;DR: The hypothesis that patients with platinum-sensitive recurrent serous ovarian cancer with a BRCA mutation have the greatest likelihood of benefiting from olaparib treatment is supported.

TL;DR: Poly(ADp-ribose) polymerase inhibitors have been investigated as treatment for a number of tumors, including those due to BRCA mutations, and one potent oral poly(ADP-riboses) is found to be effective.

TL;DR: Ovarian cancer patients with tumours harbouring loss-of-function mutations in HRR genes other than BRCA1/2 may constitute a small, molecularly identifiable and clinically relevant population who derive treatment benefit from olaparib similar to patients with BRCAm.

TL;DR: ARMS was more sensitive and robust at detecting defined somatic mutations than DNA sequencing on clinical samples where the predominant sample type was FF-PET, and improved both the sensitivity and speed of analysis compared with sequencing.

TL;DR: Progression-free survival (PFS) of patients with BRAF+ tumour and cfDNA was not significantly different compared with tumour BRAF+, indicating that cfDNA BRAF detection is not associated with poorer prognosis on PFS in stage III/IV advanced melanoma.